Selective Role of the Catalytic PI3K Subunit p110β in Impaired Higher Order Cognition in Fragile X Syndrome

Cell Reports

Volumn 11, Issue 5, 2015, Pages 681-688

  Gross, Christina ^a   Raj, Nisha ^a   Molinaro, Gemma ^c   Allen, Amanda G ^a,b   Whyte, Alonzo J ^a,b   Gibson, Jay R ^c   Huber, Kimberly M ^c   Gourley, Shannon L ^a,b   Bassell, Gary J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; METABOTROPIC RECEPTOR 5; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P100; PROTEIN P100BETA; UNCLASSIFIED DRUG; FMR1 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DECISION MAKING; DENDRITIC SPINE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FEMALE; FRAGILE X SYNDROME; GENE SILENCING; KNOCKOUT MOUSE; MALE; MOUSE; NESTING; NONHUMAN; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; TRANSLATION REGULATION; UPREGULATION; ANIMAL; CHEMISTRY; COGNITION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; COGNITION; DENDRITIC SPINES; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MALE; MICE; MICE, KNOCKOUT; PREFRONTAL CORTEX; PROTEIN BIOSYNTHESIS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84933670503     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.03.065     Document Type: Article

References (28)

1. Afonso V.M., Sison M., Lovic V., Fleming A.S. Medial prefrontal cortex lesions in the female rat affect sexual and maternal behavior and their sequential organization. Behav. Neurosci. 2007, 121:515-526.
2. Ascano M., Mukherjee N., Bandaru P., Miller J.B., Nusbaum J.D., Corcoran D.L., Langlois C., Munschauer M., Dewell S., Hafner M., et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012, 492:382-386.
3. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
4. Bhakar A.L., Dölen G., Bear M.F. The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 2012, 35:417-443.
5. Bhattacharya A., Kaphzan H., Alvarez-Dieppa A.C., Murphy J.P., Pierre P., Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76:325-337.
6. Bi L., Okabe I., Bernard D.J., Nussbaum R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome 2002, 13:169-172.
7. Busquets-Garcia A., Gomis-González M., Guegan T., Agustín-Pavón C., Pastor A., Mato S., Pérez-Samartín A., Matute C., de la Torre R., Dierssen M., et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat. Med. 2013, 19:603-607.
8. Dalley J.W., Cardinal R.N., Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev. 2004, 28:771-784.
9. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
10. Deacon R.M. Assessing nest building in mice. Nat. Protoc. 2006, 1:1117-1119.
11. Gibson J.R., Bartley A.F., Hays S.A., Huber K.M. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J.Neurophysiol. 2008, 100:2615-2626.
12. Gonçalves J.T., Anstey J.E., Golshani P., Portera-Cailliau C. Circuit level defects in the developing neocortex of Fragile X mice. Nat. Neurosci. 2013, 16:903-909.
13. Gourley S.L., Olevska A., Zimmermann K.S., Ressler K.J., Dileone R.J., Taylor J.R. The orbitofrontal cortex regulates outcome-based decision-making via the lateral striatum. Eur. J. Neurosci. 2013, 38:2382-2388.
14. Gross C., Bassell G.J. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor. Mol. Med. 2012, 18:336-345.
15. Gross C., Nakamoto M., Yao X., Chan C.B., Yim S.Y., Ye K., Warren S.T., Bassell G.J. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J.Neurosci. 2010, 30:10624-10638.
16. Gross C., Chang C.-W., Kelly S.M., Bhattacharya A., McBride S.M.J., Danielson S.W., Jiang M.Q., Chan C.B., Ye K., et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in Fragile X syndrome. Cell Reports 2015, 11:727-736. this issue.
17. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., Meek S., Smith A.J., Okkenhaug K., Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl. Acad. Sci. USA 2008, 105:8292-8297.
18. Hays S.A., Huber K.M., Gibson J.R. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J.Neurosci. 2011, 31:14223-14234.
19. Kumari D., Bhattacharya A., Nadel J., Moulton K., Zeak N.M., Glicksman A., Dobkin C., Brick D.J., Schwartz P.H., Smith C.B., et al. Identification of fragile X syndrome-specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Human Mutat. 2014, 35:1485-1494.
20. Miyashiro K.Y., Beckel-Mitchener A., Purk T.P., Becker K.G., Barret T., Liu L., Carbonetto S., Weiler I.J., Greenough W.T., Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003, 37:417-431.
21. Oretti R., Bano S., Morgan C.J., Badawy A.A., Bonner A., Buckland P., McGuffin P. Prevention by cycloheximide of the audiogenic seizures and tryptophan metabolic disturbances of ethanol withdrawal in rats. Alcohol. 1996, 31:243-247.
22. Osterweil E.K., Krueger D.D., Reinhold K., Bear M.F. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J.Neurosci. 2010, 30:15616-15627.
23. Rong R., Ahn J.Y., Huang H., Nagata E., Kalman D., Kapp J.A., Tu J., Worley P.F., Snyder S.H., Ye K. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat. Neurosci. 2003, 6:1153-1161.
24. Sharma A., Hoeffer C.A., Takayasu Y., Miyawaki T., McBride S.M., Klann E., Zukin R.S. Dysregulation of mTOR signaling in fragile X syndrome. J.Neurosci. 2010, 30:694-702.
25. Sutton M.A., Schuman E.M. Dendritic protein synthesis, synaptic plasticity, and memory. Cell 2006, 127:49-58.
26. Thomas A.M., Bui N., Graham D., Perkins J.R., Yuva-Paylor L.A., Paylor R. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav. Brain Res. 2011, 223:310-321.
27. Weiler I.J., Spangler C.C., Klintsova A.Y., Grossman A.W., Kim S.H., Bertaina-Anglade V., Khaliq H., de Vries F.E., Lambers F.A., Hatia F., et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc. Natl. Acad. Sci. USA 2004, 101:17504-17509.
28. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.